Literature DB >> 30741898

Cross-cultural Adaption and Validation of the Zurich Chronic Middle Ear Inventory Translated Into Italian (ZCMEI-21-It)-a Prospective Multicenter Study.

Massimo Ralli1, Nicola Quaranta2, Andrea Canale3, Christof Röösli4, Claudia Milella1, Valentina De Robertis2, Giulia De Soccio1, Antonio Greco1, Giovanni Ralli1, Roberto Albera3, Marco de Vincentiis1, Alexander M Huber4, David Bächinger4.   

Abstract

OBJECTIVE: There are no instruments available to comprehensively assess health-related quality of life (HRQoL) in chronic otitis media (COM) in Italian-speaking countries. The Zurich chronic middle ear inventory (ZCMEI-21) is a well-established instrument for the assessment of HRQoL in COM. The objective of this study was to translate and cross-culturally adapt the ZCMEI-21 into Italian and validate this questionnaire for measuring HRQoL in patients with COM. STUDY
DESIGN: Prospective multicenter study.
SETTING: Three University hospitals (northern Italy, central Italy, southern Italy). PATIENTS: Adult patients suffering from COM (n = 128). INTERVENTION: Following international guidelines, the ZCMEI-21 was translated into Italian (ZCMEI-21-It). Validation was performed by psychometric test statistics. Moreover, ZCMEI-21-It total and subscale scores were compared and correlated with 1) the scores of the original validation study, 2) to a question that directly addresses HRQoL, and 3) to the scores of the EQ-5D-5L, a generic questionnaire assessing HRQoL.
RESULTS: From three study centers, a total of 128 patients with COM were included. Cronbach's α was 0.86 indicating a high reliability. Between the ZCMEI-21-It total score and the question that directly addresses HRQoL, we found a strong correlation (r = 0.62, p < 0.0001). Between the ZCMEI-21-It total score and the EQ-5D-5L scores, we expectedly found moderate correlations (descriptive system score: r = 0.39, p < 0.0001; visual analog scale: r = 0.30, p = 0.008).
CONCLUSION: We translated the ZCMEI-21 questionnaire into Italian and validated the ZCMEI-21-It in a prospective multicenter study. The ZCMEI-21-It is the first instrument that comprehensively assesses relevant dimensions of HRQoL in Italian-speaking patients affected by COM.

Entities:  

Mesh:

Year:  2019        PMID: 30741898     DOI: 10.1097/MAO.0000000000002131

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  5 in total

1.  Establishing the minimal clinically important difference (MCID) of the Zurich Chronic Middle Ear Inventory (ZCMEI-21) in patients treated for chronic middle ear disease.

Authors:  David Bächinger; Robert Mlynski; Nora M Weiss
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-27       Impact factor: 2.503

2.  Validation of a Spanish version of the health-related quality of life (HRQoL) measure for Chronic Otitis Media (COMQ-12).

Authors:  Ana M Otoya-Tono; Lucía C Pérez-Herrera; Daniel Peñaranda; Sergio Moreno-López; Ricardo Sánchez-Pedraza; Juan Manuel García; John S Phillips; Augusto Peñaranda
Journal:  Health Qual Life Outcomes       Date:  2020-11-10       Impact factor: 3.186

3.  A novel Turkish instrument for assessing quality of life in chronic otitis media –translation and validation of Zurich chronic middle ear inventory

Authors:  Belgin Tutar; Ziya Saltürk; Güler Berkiten; Muhammet Enis Ekincioğlu; Semih Karaketir; Melis Ece Arkan; Muhammed Fatih Akgün; Ayça Başkadem Yılmazer; Ercan Kulak; David Baechinger; Yavuz Uyar
Journal:  Turk J Med Sci       Date:  2020-12-17       Impact factor: 0.973

4.  Mastoid cavity obliteration leads to a clinically significant improvement in health-related quality of life.

Authors:  Nora M Weiss; David Bächinger; Jannik Botzen; Wilma Großmann; Robert Mlynski
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-03-06       Impact factor: 2.503

5.  Mapping the ChOLE classification to hearing outcomes and disease-specific health-related quality of life.

Authors:  Nora M Weiss; David Bächinger; Adrian Rrahmani; Hans E Bernd; Alexander Huber; Robert Mlynski; Christof Röösli
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-05-05       Impact factor: 2.503

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.